ATCT-13 BEVACIZUMAB, RADIATION THERAPY (RT) AND TEMOZOLOMIDE FOLLOWED BY BEVACIZUMAB AND TEMOZOLOMIDE WITH CONTINUATION OF BEVACIZUMAB BEYOND PROGRESSION: A PHASE II TRIAL

Podobne zapisy

• AT-22 PHASE II TRIAL OF BEVACIZUMAB, RADIATION THERAPY (RT) AND TEMOZOLOMIDE FOLLOWED BY BEVACIZUMAB AND TEMOZOLOMIDE WITH CONTINUATION OF BEVACIZUMAB BEYOND PROGRESSION
  od: Ghiaseddin, Ashley, i wsp.
  Wydane: (2014)
• ATCT-01 PHASE II STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RILOTUMUMAB AND BEVACIZUMAB (BEV) IN SUBJECTS WITH RECURRENT MALIGNANT GLIOMA (MG)
  od: Affronti, Mary L., i wsp.
  Wydane: (2015)
• The Addition of Bevacizumab to Standard Radiation Therapy and Temozolomide Followed by Bevacizumab, Temozolomide and Irinotecan for Newly Diagnosed Glioblastoma
  od: Vredenburgh, James J., i wsp.
  Wydane: (2011)
• Adjunctive perampanel for glioma-associated epilepsy()
  od: Dunn-Pirio, Anastasie M., i wsp.
  Wydane: (2018)
• QLIF-22. MAINTENANCE OF HEALTH RELATED QUALITY OF LIFE (QOL) BEYOND PROGRESSION IN NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS TREATED WITH BEVACIZUMAB
  od: Peters, Katherine B, i wsp.
  Wydane: (2017)